Solid Biosciences (SLDB) Operating Leases: 2019-2024
Historic Operating Leases for Solid Biosciences (SLDB) over the last 6 years, with Sep 2024 value amounting to $21.6 million.
- Solid Biosciences' Operating Leases fell 6.67% to $21.6 million in Q3 2024 from the same period last year, while for Sep 2024 it was $21.6 million, marking a year-over-year decrease of 6.67%. This contributed to the annual value of $22.7 million for FY2023, which is 6.47% down from last year.
- Per Solid Biosciences' latest filing, its Operating Leases stood at $21.6 million for Q3 2024, which was down 2.05% from $22.1 million recorded in Q2 2024.
- Solid Biosciences' Operating Leases' 5-year high stood at $24.5 million during Q2 2022, with a 5-year trough of $70,000 in Q1 2022.
- In the last 3 years, Solid Biosciences' Operating Leases had a median value of $23.2 million in 2023 and averaged $21.2 million.
- In the last 5 years, Solid Biosciences' Operating Leases tumbled by 96.46% in 2022 and then soared by 34,060.00% in 2023.
- Quarterly analysis of 5 years shows Solid Biosciences' Operating Leases stood at $2.4 million in 2020, then crashed by 88.63% to $275,000 in 2021, then skyrocketed by 8,728.73% to $24.3 million in 2022, then decreased by 6.47% to $22.7 million in 2023, then dropped by 6.67% to $21.6 million in 2024.
- Its Operating Leases stands at $21.6 million for Q3 2024, versus $22.1 million for Q2 2024 and $22.5 million for Q1 2024.